[SER140]-PLP(139-151) is a fragment of myelin proteolipid protein, induce experimental autoimmune encephalomyelitis (EAE).
![[SER140]-PLP(139-151)(CAS 122018-58-0)](https://img.creative-peptides.com/structure/122018-58-02d.png)
CAT No: R1135
CAS No:122018-58-0
Synonyms/Alias:122018-58-0;Proteolipid protein (139-151);[SER140]-PLP(139-151);PLP(139-151)TFA;AKOS024457171;NCGC00167265-01;DA-56936;SER140-PLP(139-151)?;CAS 122018-58-0;G78392;
Chemical Name:(S,Z)-3-((Z)-(((S)-1-((2S,3Z,6Z,8S,9Z,11S,12Z,14S,15Z,18Z,20S,21Z,23S,24Z,26S)-2-((1H-imidazol-5-yl)methyl)-11-((1H-indol-3-yl)methyl)-26-amino-14-(4-aminobutyl)-4,7,10,13,16,19,22,25-octahydroxy-23-(hydroxymethyl)-27-(1H-imidazol-5-yl)-8,20-diisobutyl-3
[SER140]-PLP(139-151) is a synthetic peptide fragment derived from the proteolipid protein (PLP) sequence, specifically encompassing amino acids 139 to 151. As a well-characterized epitope, this peptide is widely recognized for its role in experimental models of demyelinating diseases, particularly in the context of neuroimmunological research. Its defined sequence and immunogenic properties make it a valuable reagent for probing T cell responses and investigating autoimmune mechanisms related to central nervous system (CNS) disorders. The biochemical stability and sequence fidelity of [SER140]-PLP(139-151) allow for reproducible results in both in vitro and in vivo experimental settings, supporting its broad relevance for peptide-based studies in neuroscience and immunology.
Antigen-Specific T Cell Activation Studies: In immunological research, [SER140]-PLP(139-151) serves as a critical tool for eliciting and characterizing antigen-specific T cell responses. Its sequence corresponds to a dominant encephalitogenic epitope in rodent models, enabling researchers to induce and monitor T cell proliferation, cytokine secretion, and phenotypic changes upon peptide stimulation. This application is essential for dissecting the cellular and molecular mechanisms underlying antigen recognition, tolerance, and immune regulation within the CNS.
Experimental Autoimmune Encephalomyelitis (EAE) Induction: The peptide is extensively utilized in the induction of experimental autoimmune encephalomyelitis, a widely accepted animal model for studying multiple sclerosis and related demyelinating conditions. By administering the peptide in combination with suitable adjuvants, investigators can reproducibly trigger CNS-directed autoimmunity, allowing for the evaluation of disease onset, progression, and therapeutic interventions. This use facilitates the exploration of pathogenic immune pathways and the assessment of candidate immunomodulatory compounds.
Epitope Mapping and Immunodominance Analysis: [SER140]-PLP(139-151) is employed in epitope mapping studies to identify and validate immunodominant regions recognized by T cells in various genetic backgrounds. Through ex vivo assays, the peptide enables detailed characterization of T cell repertoires, epitope specificity, and cross-reactivity. Such analyses are critical for understanding the molecular determinants of antigenicity and for designing peptide-based immunotherapies or tolerance-inducing protocols.
Peptide-MHC Binding and Structural Studies: The defined sequence of this peptide makes it an ideal substrate for investigating peptide-MHC (major histocompatibility complex) interactions. Researchers utilize it to study binding affinities, structural conformations, and the presentation of antigenic peptides by MHC class II molecules. These experiments provide valuable insights into the structural basis of immune recognition and inform the rational design of modified peptides with altered immunogenic properties.
In vitro Immune Assays and Functional Screening: In addition to in vivo applications, the peptide is widely used in cell-based assays to evaluate immune cell function, including proliferation, cytokine production, and cytotoxic responses. Its predictable activity facilitates the screening of T cell clones, assessment of antigen processing, and validation of immunological reagents. These in vitro studies support the development of novel experimental approaches and contribute to a deeper understanding of peptide-mediated immune modulation.
2. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
4. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More